Maze Therapeutics (MAZE) Competitors $10.52 +0.41 (+4.06%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MAZE vs. INDV, IDYA, EWTX, IMCR, MESO, TVTX, GPCR, EVO, JANX, and ADPTShould you be buying Maze Therapeutics stock or one of its competitors? The main competitors of Maze Therapeutics include Indivior (INDV), IDEAYA Biosciences (IDYA), Edgewise Therapeutics (EWTX), Immunocore (IMCR), Mesoblast (MESO), Travere Therapeutics (TVTX), Structure Therapeutics (GPCR), Evotec (EVO), Janux Therapeutics (JANX), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry. Maze Therapeutics vs. Indivior IDEAYA Biosciences Edgewise Therapeutics Immunocore Mesoblast Travere Therapeutics Structure Therapeutics Evotec Janux Therapeutics Adaptive Biotechnologies Indivior (NASDAQ:INDV) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation. Is INDV or MAZE more profitable? Maze Therapeutics has a net margin of 0.00% compared to Indivior's net margin of -3.96%. Maze Therapeutics' return on equity of 0.00% beat Indivior's return on equity.Company Net Margins Return on Equity Return on Assets Indivior-3.96% -241.73% 15.09% Maze Therapeutics N/A N/A N/A Does the media prefer INDV or MAZE? In the previous week, Indivior and Indivior both had 3 articles in the media. Indivior's average media sentiment score of 1.68 beat Maze Therapeutics' score of -0.27 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Maze Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, INDV or MAZE? Indivior has higher revenue and earnings than Maze Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndivior$1.17B1.34$2M-$0.31-36.61Maze Therapeutics$167.50M2.72N/AN/AN/A Does the MarketBeat Community prefer INDV or MAZE? Indivior received 5 more outperform votes than Maze Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformIndiviorOutperform Votes11100.00% Underperform VotesNo VotesMaze TherapeuticsOutperform Votes6100.00% Underperform VotesNo Votes Do insiders & institutionals have more ownership in INDV or MAZE? 60.3% of Indivior shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate INDV or MAZE? Indivior presently has a consensus price target of $15.00, suggesting a potential upside of 32.16%. Maze Therapeutics has a consensus price target of $25.67, suggesting a potential upside of 146.79%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than Indivior.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indivior 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 SummaryMaze Therapeutics beats Indivior on 6 of the 11 factors compared between the two stocks. Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAZE vs. The Competition Export to ExcelMetricMaze TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$455.49M$2.94B$5.40B$8.49BDividend YieldN/A1.72%5.22%4.11%P/E RatioN/A30.9526.7119.93Price / Sales2.72410.01395.44119.84Price / CashN/A168.6838.2534.62Price / BookN/A3.316.854.59Net IncomeN/A-$72.17M$3.23B$248.19M7 Day Performance14.79%6.36%5.35%2.21%1 Month Performance13.91%9.80%13.31%16.23%1 Year PerformanceN/A-27.03%17.58%8.00% Maze Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAZEMaze TherapeuticsN/A$10.52+4.1%$25.67+144.0%N/A$460.74M$167.50M0.00121Earnings ReportGap UpINDVIndivior3.3063 of 5 stars$11.34+2.4%$15.00+32.3%-33.1%$1.56B$1.17B-32.401,164News CoveragePositive NewsIDYAIDEAYA Biosciences3.7852 of 5 stars$17.82+2.9%$54.27+204.6%-51.3%$1.56B$7M-5.4080Positive NewsEWTXEdgewise Therapeutics2.9231 of 5 stars$14.78+2.3%$40.22+172.1%-20.8%$1.55BN/A-9.8560Positive NewsIMCRImmunocore2.929 of 5 stars$30.37+4.5%$58.13+91.4%-39.1%$1.52B$333.58M-31.97320Positive NewsMESOMesoblast1.8686 of 5 stars$11.72-1.9%$18.00+53.6%+57.9%$1.50B$5.67M0.0080Gap DownTVTXTravere Therapeutics3.0659 of 5 stars$16.80-20.6%$31.79+89.2%+184.6%$1.49B$273.53M-4.10460Positive NewsHigh Trading VolumeGPCRStructure Therapeutics2.1502 of 5 stars$25.17+3.0%$78.00+209.9%-31.1%$1.44BN/A-34.01136EVOEvotec1.5232 of 5 stars$4.06+3.0%$5.93+46.1%-21.9%$1.44B$788.22M0.004,200Gap DownJANXJanux Therapeutics2.7762 of 5 stars$24.28+4.3%$95.25+292.3%-47.1%$1.44B$9.34M-20.7530Positive NewsADPTAdaptive Biotechnologies3.5906 of 5 stars$9.05+1.6%$9.83+8.7%+160.7%$1.37B$189.53M-8.30790News CoveragePositive NewsGap Down Related Companies and Tools Related Companies Indivior Competitors IDEAYA Biosciences Competitors Edgewise Therapeutics Competitors Immunocore Competitors Mesoblast Competitors Travere Therapeutics Competitors Structure Therapeutics Competitors Evotec Competitors Janux Therapeutics Competitors Adaptive Biotechnologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAZE) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
